Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Lyette S Richards"'
Autor:
Robert Hermann, Juergen Borlak, Mathias Locher, Georg Niebch, Norbert G. Knebel, Lyette S Richards
Publikováno v:
European Journal of Clinical Pharmacology. 58:795-802
The antiepileptic drugs (AEDs) retigabine (RGB) and lamotrigine (LTG) undergo predominantly N-glucuronidation and renal excretion. This study was performed to evaluate potential pharmacokinetic interactions between both AEDs.Twenty-nine healthy male
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fca5a5186c22b800a528fa5fe3485ba9
https://doi.org/10.1007/s00228-003-0558-6
https://doi.org/10.1007/s00228-003-0558-6
Autor:
Jeffrey Paul, Norbert G. Knebel, Katharina Erb, Lyette S Richards, Hans‐Peter Cnota, Robert Hermann, Geraldine M. Ferron, Peter Ruus, Steven M. Troy
Publikováno v:
Clinical Pharmacology & Therapeutics. 73:61-70
Background The novel antiepileptic drug retigabine is the first selective M-current potassium channel opener for KCNQ2/3 and KCNQ3/5 channels. Retigabine undergoes phase II metabolism (N-glucuronidation, acetylation) exclusively and renal excretion.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85f7e9c08dbe3bef91828792b989d4e7
https://doi.org/10.1067/mcp.2003.12
https://doi.org/10.1067/mcp.2003.12
Autor:
Lyette S. Richards, Joseph Boni, David R. Hicks, Soong T. Chiang, Joan M. Korth-Bradley, Leslie Z. Benet
Publikováno v:
Clinical Pharmacokinetics. 39:459-469
Background: For many racemic drugs, bioequivalence assessment based on isomer-nonspecific assays is appropriate because enantiomeric area under the concentration-time curve (AUC) exposure ratios are close to unity. Use of nonspecific methods in cases
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b89a3d77c881b80d3130534507a25385
https://doi.org/10.2165/00003088-200039060-00006
https://doi.org/10.2165/00003088-200039060-00006
Autor:
Joan M. Korth-Bradley, Patrick Martin, Joseph Boni, Philip D. Walson, Robert M. Rennebohm, Donna Simcoe, Lyette S. Richards
Publikováno v:
Clinical Therapeutics. 21:1715-1724
This was a single-center, open-label, single-dose pharmacokinetic study of etodolac in pediatric and adolescent patients with stable juvenile rheumatoid arthritis (JRA). Eleven male and female patients with JRA (8.1 to 14.8 years of age, weighing 26.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c13cd39b62f47af94b8353ec6e05dfd8
https://doi.org/10.1016/s0149-2918(99)80050-2
https://doi.org/10.1016/s0149-2918(99)80050-2
Autor:
Jeffrey Paul, Richard Fruncillo, Joel A Posener, Lyette S Richards, Alice I. Nichols, Jessica A Behrle
Publikováno v:
Journal of Bioequivalence & Bioavailability.
Background: Desvenlafaxine (administered as desvenlafaxine succinate) is a serotonin-norepinephrine reuptake inhibitor approved for treatment of major depressive disorder. Because it is primarily eliminated unchanged by renal excretion, it is importa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::88b58d90c0381cac891730db7b76b39f
https://doi.org/10.4172/jbb.1000140
https://doi.org/10.4172/jbb.1000140
Publikováno v:
Journal of Bioequivalence & Bioavailability.
The serotonin-norepinephrine reuptake inhibitor desvenlafaxine has linear and dose-proportional pharmacokinetics from 25 to 900 mg. The effect of diet on the pharmacokinetics, safety, and tolerability of desvenlafaxine in healthy volunteers (N=33) wa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ac7b667ec730b9bcb30e6f37d6890e0c
https://doi.org/10.4172/jbb.1000106
https://doi.org/10.4172/jbb.1000106
Autor:
Lyette S Richards, Jeffrey Paul, Vernon D. Parker, Jessica A Behrle, Richard Fruncillo, Alice I. Nichols, Joel A Posener
Publikováno v:
Journal of Bioequivalence & Bioavailability.
Background and Objective: Desvenlafaxine (administered as desvenlafaxine succinate) is approved for the treatment of major depressive disorder (MDD). If eliminated by the kidney, desvenlafaxine may have more favorable pharmacokinetic or drug-drug int
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ec3d565a137e9e847f23e79894b5635
https://doi.org/10.4172/jbb.1000105
https://doi.org/10.4172/jbb.1000105
Publikováno v:
International journal of clinical pharmacology and therapeutics. 49(1)
BACKGROUND Desvenlafaxine (administered as desvenlafaxine succinate), the major active metabolite of venlafaxine, is a new serotonin-norepinephrine reuptake inhibitor (SNRI) approved for the treatment of major depressive disorder (MDD). OBJECTIVE To
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d916551996ab8262f473676124e17150
https://pubmed.ncbi.nlm.nih.gov/21176719
https://pubmed.ncbi.nlm.nih.gov/21176719
Autor:
Richard Fruncillo, Steven M. Troy, Lyette S Richards, Geraldine M. Ferron, John Getsy, Jeffrey Paul, Norbert Knebel
Publikováno v:
Journal of clinical pharmacology. 42(2)
Retigabine, a first-in-class selective M-current potassium channel opener, is a novel antiepileptic compound currently in clinical development. The purpose of this randomized placebo-controlled study was to assess retigabine oral safety and pharmacok
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a15f016b7cf906399719dc4562eef90
https://pubmed.ncbi.nlm.nih.gov/11831540
https://pubmed.ncbi.nlm.nih.gov/11831540
Publikováno v:
Clinical Pharmacology & Therapeutics. 79:P25-P25
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::12ca4f87f0f50989b976c521dc40f2d3
https://doi.org/10.1016/j.clpt.2005.12.089
https://doi.org/10.1016/j.clpt.2005.12.089